Trial Information

Summary: Acute attacks of hives (hereditary angioedema)

An Ascending Four Dose Placebo Controlled Study to Assess the Efficacy and Tolerability of DX-88 (recombinant plasma kallikrein inhibitor) Administered Following Onset of Acute Attacks of Hereditary Angioedema.

You or your child may be eligible to participate in this research study being conducted by Albert Einstein College of Medicine.

You or your child may be eligible if you or your child:

• Is 10 years of age or older
• Have a previously confirmed diagnosis and history of heredity angioedema
• Can report to the study site no later than 4 hours after the onset of an attack

You or your child may not be eligible if you or your child:

• Has a serious intercurrent illness or active infection
• Have received an experimental drug or device within 30 days prior to study entry
• Have been diagnosed with acquired angioedema
• Is female and pregnant or lactating

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:28 AM